Neoadjuvant capecitabine and oxaliplatin (CAPOX) followed by chemoradiation (CRT) in high-risk rectal cancer: A single-institution experience

被引：0
|
作者：
Ahmad, Saif
Parashar, Deepak
Jephcott, Catherine Rachel
Ford, Hugo
Wilson, Charles
机构：
[1] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England
[2] MRC, Biostat Unit, Cambridge CB2 2BW, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14100
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Oncologic Outcomes of Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Single-institution Experience
    Leong, Yiat Horng
    Leong, Cheng Nang
    Tay, Guan Sze
    Sim, Richard
    Lopes, Gilberto
    Low, Wilson
    Choo, Bok Ai
    Tey, Jeremy
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2014, 43 (12) : 569 - 575
  • [2] Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer
    Hasegawa, Junichi
    Nishimura, Junichi
    Mizushima, Tsunekazu
    Miyake, Yasuhiro
    Kim, Ho Min
    Takemoto, Hiroyoshi
    Tamagawa, Hroshi
    Noura, Shingo
    Fujii, Makoto
    Fujie, Yujiro
    Kato, Takeshi
    Miwa, Hideaki
    Takemasa, Ichiro
    Ikeda, Masataka
    Yamamoto, Hirofumi
    Sekimoto, Mistugu
    Nezu, Riichiro
    Doki, Yuichiro
    Mori, Masaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 1079 - 1087
  • [3] Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer
    Junichi Hasegawa
    Junichi Nishimura
    Tsunekazu Mizushima
    Yasuhiro Miyake
    Ho Min Kim
    Hiroyoshi Takemoto
    Hroshi Tamagawa
    Shingo Noura
    Makoto Fujii
    Yujiro Fujie
    Takeshi Kato
    Hideaki Miwa
    Ichiro Takemasa
    Masataka Ikeda
    Hirofumi Yamamoto
    Mistugu Sekimoto
    Riichiro Nezu
    Yuichiro Doki
    Masaki Mori
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1079 - 1087
  • [4] EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer
    Dewdney, A.
    Capdevila, J.
    Glimelius, B.
    Cervantes, A.
    Tait, D. M.
    Brown, G.
    Wotherspoon, A.
    de Castro, D. Gonzalez
    Chua, Y. J.
    Wong, R.
    Barbachano, Y.
    Oates, J. R.
    Chau, I.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] NEOADJUVANT CHEMOTHERAPY CAPECITABINE AND OXALIPLATIN (XELOX) COMBINED WITH BEVACIZUMAB FOR HIGH-RISK LOCALIZED RECTAL CANCER
    Takeshi, Kato
    Junichi, Hasegawa
    Tsunekazu, Mizushima
    Ho, Kim
    Yasuhiro, Miyake
    Taishi, Hata
    Junichi, Nishimura
    Kazumasa, Ikenaga
    Hiroyoshi, Takemoto
    Hiroshi, Tamagawa
    Shingo, Noura
    Masayuki, Ohue
    Kouhei, Murata
    Yuichiro, Fujie
    Mutsumi, Fukunaga
    Ichirou, Takemasa
    Masataka, Ikeda
    Hirofumi, Yamamoto
    Mistugu, Sekimoto
    Riichirou, Nezu
    Yuichiro, Doki
    Masaki, Mori
    ANNALS OF ONCOLOGY, 2014, 25 : 95 - 95
  • [6] HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab
    Sclafani, F.
    Roy, A.
    Cunningham, D.
    Wotherspoon, A.
    Peckitt, C.
    Gonzalez de Castro, D.
    Tabernero, J.
    Glimelius, B.
    Cervantes, A.
    Eltahir, Z.
    Oates, J.
    Chau, I.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 3123 - 3128
  • [7] HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab
    Sclafani, Francesco
    Roy, Amitesh Chandra
    Chau, Ian
    Wotherspoon, Andrew
    Peckitt, Clare
    Dewdney, Alice
    Oates, Jacqueline Rose
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.
    Dewdney, Alice
    Chau, Ian
    Capdevila, Jaume
    Glimelius, Bengt
    Cervantes-Ruiperez, Andres
    Tait, Diana M.
    Brown, Gina
    Wotherspoon, Andrew
    de Castro, David Gonzalez
    Wilson, Sanna Hulkki
    Chua, Yu Jo
    Wong, Rachel
    Barbachano, Yolanda
    Oates, Jacqueline Rose
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
    Leichman, Cynthia Gail
    McDonough, Shannon L.
    Smalley, Stephen R.
    Billingsley, Kevin G.
    Lenz, Heinz-Josef
    Beldner, Matthew A.
    Hezel, Aram F.
    Velasco, Mario R.
    Guthrie, Katherine A.
    Blanke, Charles D.
    Hochster, Howard S.
    CLINICAL COLORECTAL CANCER, 2018, 17 (01) : E121 - E125
  • [10] IMPROVED RO RESECTION WITH SELECTIVE NEOADJUVANT CAPECITABINE/OXALIPLATIN AND CHEMORADIATION FOR RECTAL CANCER
    Zachariah, A.
    Davies, R.
    Muscroft, T.
    Odogwu, S.
    Church, Ft.
    Sidebotham, J.
    Hartley, A.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S281 - S281
12345